ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease



Similar documents
DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

GENERAL HEART DISEASE KNOW THE FACTS

Listen to your heart: Good Cardiovascular Health for Life

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Diabetes and Heart Disease

The Burden Of Diabetes And The Promise Of Biomedical Research

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

Malmö Preventive Project. Cardiovascular Endpoints

Statins and Risk for Diabetes Mellitus. Background

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

CARDIAC CARE. Giving you every advantage

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

STROKE PREVENTION IN ATRIAL FIBRILLATION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Malmö Preventive Project. Cardiovascular Endpoints

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

HEDIS CY2012 New Measures

Cardiovascular Endpoints

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

Carbohydrate and Lipid Disorders and Relevant Considerations in Persons with Spinal Cord Injury

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

DR. Trinh Thi Kim Hue

Perioperative Cardiac Evaluation

Mortality Associated with Diabetes

Guidelines for the management of hypertension in patients with diabetes mellitus

Innovation Platform: Sudden Cardiac Death

Design and principal results

Rx Updates New Guidelines, New Medications What You Need to Know

Baskets of Care Diabetes Subcommittee

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Snoring and Obstructive Sleep Apnea (updated 09/06)

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat?

Cardiac Rehabilitation (Outpatient Phase II) Corporate Medical Policy. Medical Policy

Type 2 Diabetes: Making Prevention a Priority The IGT Care Call Project

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Karen Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc.

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

Disability Evaluation Under Social Security

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease

Cardiovascular Endpoints

Diagnosis, classification and prevention of diabetes

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Population Health Management Program

Diabetes: The Numbers

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Is Insulin Effecting Your Weight Loss and Your Health?

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Markham Stouffville Hospital

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

Duration of Dual Antiplatelet Therapy After Coronary Stenting

DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa

Introduction. Pathogenesis of type 2 diabetes

definition and diagnosis of diabetes mellitus and intermediate hyperglycemia Report of a WHO/IDF Consultation

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

SHORT CLINICAL GUIDELINE SCOPE

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Main Effect of Screening for Coronary Artery Disease Using CT

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Protocol. Cardiac Rehabilitation in the Outpatient Setting

Stroke Prevention in Primary Care

The Heart and Vascular Institute at Englewood Hospital and Medical Center

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

How To Understand And Understand The Concept Of Intermediate Hyperglycaemia

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Type 1 Diabetes ( Juvenile Diabetes)

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

Antiplatelet and Antithrombotics From clinical trials to guidelines

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

Family History and Diabetes. Practical Genomics for the Public Health Professional

Deakin Research Online

Screening for for Cardiovascular Disease and Risk Factors

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Diabetes Complications

How To Treat An Elderly Patient

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke

Vascular Risk Reduction: Addressing Vascular Risk

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Connecticut Diabetes Statistics

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

Transcription:

Diabetes, prediabetes and cardiovascular disease

Classes of recommendations Levels of evidence

Recommended treatment targets for patients with diabetes and CAD

Definition, classification and screening of diabetes and pre-diabetic glucose abnormalities

Criteria used for gluco-metabolic classification from WHO (1999) and ADA (1997 and 2003)

Fasting and post-load glucose levels identify different individuals with asymptomatic diabetes Adapted from the DECODE study group

Appropriate methods for the early detection of people with high risk for diabetes

FINnish Diabetes Risk Score (FINDRISC) to address 10 year risk of type 2 diabetes in adults. Available www.diabetes.fi/english

Epidemiology of diabetes, IGH and cardiovascular risk

Age and gender-specific prevalence of diabetes in 13 European population-based cohorts Adapted from the DECODE study group

Identification of subjects at high risk for cardiovascular disease or diabetes

Definition the metabolic syndrome according to International Diabetes Federation

Findings in lifestyle intervention studies aiming at prevention of type 2 diabetes in people with impaired glucose tolerance

Treatment to reduce cardiovascular risk

Suggested policy for the selection of glucose lowering therapy according to the glucometabolic situation

Mean efficacy of pharmacological treatment options in patients with type 2 diabetes

Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes

Dyslipidemia

Diabetic patients in major secondary prevention trials with statins and risk reduction in patients with and without diabetes

Blood pressure and diabetes

Management of cardiovascular risk Coronary artery disease

Treatment options based on accumulated evidence

Risk assessment of patients with diabetes and acute coronary syndromes

Management of cardiovascular risk acute coronary syndromes

Trials addressing diabetes and revascularisation for multivessel disease

Diabetes, prediabetes and cardiovascular disease Revascularisation of diabetic patients with multivessel disease in the stent area

Heart failure and diabetes

Arrhythmias, atrial fibrillation and sudden death

Peripheral and cerebrovascular disease

Investigation of the peripheral circulation in diabetic patients

Measurement of ankle blood pressure

Stroke

Intensive care

Published trials on intensive insulin therapy in intensive care

Health economy and diabetes

Direct medical costs and percentage of health care costs for patients with type 2 diabetes in eight European countries